Assembly Biosciences Inc (NASDAQ:ASMB) Expected to Announce Quarterly Sales of $12.54 Million

Analysts expect that Assembly Biosciences Inc (NASDAQ:ASMB) will announce $12.54 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Assembly Biosciences’ earnings, with estimates ranging from $4.00 million to $36.04 million. Assembly Biosciences posted sales of $3.08 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 307.1%. The business is scheduled to issue its next quarterly earnings results on Monday, August 3rd.

According to Zacks, analysts expect that Assembly Biosciences will report full year sales of $20.36 million for the current fiscal year, with estimates ranging from $10.21 million to $40.12 million. For the next financial year, analysts forecast that the company will post sales of $15.80 million, with estimates ranging from $14.00 million to $17.60 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.22. The business had revenue of $4.08 million during the quarter, compared to analysts’ expectations of $3.82 million. Assembly Biosciences had a negative net margin of 601.75% and a negative return on equity of 45.43%.

Several brokerages have issued reports on ASMB. Mizuho reaffirmed a “buy” rating and issued a $30.00 target price on shares of Assembly Biosciences in a report on Friday, May 8th. Zacks Investment Research cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday. ValuEngine raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday, April 8th. William Blair reissued a “buy” rating on shares of Assembly Biosciences in a report on Thursday. Finally, BidaskClub raised shares of Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a report on Friday. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $39.75.

Assembly Biosciences stock traded up $0.65 during trading hours on Friday, hitting $23.81. The stock had a trading volume of 166,900 shares, compared to its average volume of 261,602. The company has a quick ratio of 12.14, a current ratio of 12.14 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $757.85 million, a P/E ratio of -6.94 and a beta of 1.26. Assembly Biosciences has a 12-month low of $8.13 and a 12-month high of $25.07. The stock’s 50-day moving average price is $20.86 and its 200-day moving average price is $18.82.

In other Assembly Biosciences news, EVP Richard James Colonno sold 7,812 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $15.04, for a total transaction of $117,492.48. Following the completion of the sale, the executive vice president now directly owns 144,821 shares of the company’s stock, valued at $2,178,107.84. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 12.42% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the business. State Street Corp increased its holdings in Assembly Biosciences by 18.4% during the first quarter. State Street Corp now owns 551,324 shares of the biopharmaceutical company’s stock valued at $8,176,000 after buying an additional 85,622 shares during the last quarter. Morgan Stanley increased its holdings in Assembly Biosciences by 169.2% during the first quarter. Morgan Stanley now owns 160,050 shares of the biopharmaceutical company’s stock valued at $2,374,000 after buying an additional 100,586 shares during the last quarter. AQR Capital Management LLC purchased a new stake in Assembly Biosciences during the first quarter valued at approximately $175,000. Two Sigma Advisers LP boosted its position in shares of Assembly Biosciences by 1.6% in the first quarter. Two Sigma Advisers LP now owns 71,200 shares of the biopharmaceutical company’s stock worth $1,056,000 after purchasing an additional 1,100 shares during the period. Finally, Atom Investors LP bought a new position in shares of Assembly Biosciences in the first quarter worth approximately $2,002,000. 88.34% of the stock is owned by institutional investors and hedge funds.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Featured Story: Channel Trading

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.